Fosun Pharma, ClavisBio ink multi-target deal worth up to $362.5M per project

On December 18, Fosun Pharma announced that its controlling subsidiary, Fosun Pharma Industrial, has entered into a strategic collaboration with biotechnology company ClavisBio. The two parties will jointly develop innovative therapies based on novel targets nominated by ClavisBio.

Screenshot source: Fosun Pharma Announcement

ClavisBio was established in March 2025 and is registered in Delaware, USA. It is a wholly-owned subsidiary established by AditumBio specifically for this collaboration through its fund, AditumBio Fund 3. AditumBio primarily engages in venture capital investments within the biotechnology sector. It was co-founded in 2019 by Joe Jimenez, former CEO of Novartis, and Dr. Mark Fishman, former President of the Novartis Institutes for BioMedical Research. AditumBio advances the clinical development of drug candidates primarily by screening and in-licensing high-potential molecules.

Under the agreement, within the stipulated five-year collaboration period, the two parties will jointly select and advance preclinical development for compounds targeting specific targets nominated by ClavisBio (up to four targets per year). For each collaboration project, ClavisBio holds an exclusive option right to develop, manufacture, and commercialize the resulting product globally, excluding mainland China, Hong Kong, and Macao. Regardless of whether ClavisBio exercises this global option, Fosun Pharma retains exclusive rights for development, manufacturing, and commercialization within mainland China, Hong Kong, and Macao.

If ClavisBio exercises its option for any given collaboration project under this agreement, Fosun Pharma is eligible to receive up to USD 362.5 million in payments related to that specific project. These payments include a non-refundable exercise fee, development and registration milestone payments, and sales milestone payments. Additionally, Fosun Pharma is entitled to receive tiered royalties based on a predetermined percentage of the net sales achieved by the product from that project within the licensed territories.

Furthermore, Fosun Pharma will acquire, at zero cost, a specified minority equity stake in the new project company to be separately established by AditumBio for the corresponding collaboration project.